Evaluation of the Pharmacokinetics, Safety, and Tolerability of IM Letrozole LEBE in Healthy Post-menopausal Women
About the study
This is a Phase I, open label, sequential, single ascending dose (SAD) study to evaluate the pharmacokinetic (PK), safety, and tolerability of Letrozole LEBE in healthy post-menopausal women.
Who can take part
You may be eligible to participate in the study if you meet the following criteria:
INCLUSION CRITERIA
Inclusion Criteria:
- Healthy post-menopausal women.
- Capable of providing informed consent.
- Weight of ≥50 kg and a BMI ≥19 and ≤39 kg/m2.
- Subjects should be able to communicate with clinic staff.
EXCLUSION CRITERIA
Exclusion Criteria:
- Subjects who have a history of allergy or hypersensitivity to letrozole or any of the inactive ingredients.
- Subjects who have a history of galactose intolerance, severe hereditary lactase deficiency glucose-galactose malabsorption.
- Subjects who have used estrogen or progesterone hormone replacement therapy, thyroid replacement therapy, oral contraceptives, androgens, luteinizing hormone (LH) releasing hormone analogs, prolactin inhibitors, or antiandrogens within prior to Screening.
- Subjects who have used: any medications including St. John's wort or any medications or products known to be potent or moderate inhibitors of CYP P450 3A4.
- Subjects who have been diagnosed with osteoporosis.
- Subjects who have an abnormality at Screening or prior to first dose that in the opinion of the investigator increases the risk of participating in the study.
- Subjects who have any clinically significant abnormal physical examination or laboratory safety findings at screening.
- Subjects who have relevant diseases or clinically significant abnormal relevant findings at Screening, as determined by medical history, physical examination, laboratory, ECG, DEXA, and breast and pelvic examination.
- Subjects who have history of any significant chronic disease.
- History of cancer within the past 5 years with the exception of non-melanoma skin cancer.
- Subjects who have a history of drug-dependence, and recent history of alcoholism or abuse of alcohol.
- Subjects who have received a drug in research or have participated in other clinical trials within 90 days, prior to dosing.
- Any other unspecified reason that, in the opinion of the investigator (or designee) or sponsor, makes the subject unsuitable for enrolment.
Study Locations
Enter your ZIP code/Postal code/PIN code to locate study sites near you:
How to Apply
Contact the study center to learn if this study is a good match for you.
Study Details
Contition
Healthy
Age
18 - 75
Phase
PHASE1
Participants Needed
90
Est. Completion Date
Jan 31, 2025
Treatment Type
INTERVENTIONAL
Sponsor
Rovi Pharmaceuticals Laboratories
ClinicalTrials.gov NCT Identifier
NCT06315205
Study Number
ROV-LEBE-2023-01
Understanding Clinical Trials
Get answers to your questions about clinical trials.What is clinical research?What does taking part in clinical trials involve?What should I ask the trial doctor?